#1 Clinical Trials Search in Europe

Minoxidil

Minoxidil, a medication originally developed to treat high blood pressure, has shown promising results in treating various forms of hair loss. This article explores recent clinical trials investigating the efficacy and safety of minoxidil for conditions like androgenetic alopecia and endocrine therapy-induced alopecia. We’ll examine different formulations, dosages, and administration methods being studied to optimize minoxidil’s hair growth-promoting effects.

Table of Contents

What is Minoxidil?

Minoxidil is a medication primarily used to treat hair loss and promote hair growth. It was originally developed as a blood pressure medication but was found to have the unexpected side effect of stimulating hair growth[1]. Minoxidil is also known by several other names, including Rogaine, Loniten, and Alostil[1].

Conditions Treated with Minoxidil

Minoxidil is primarily used to treat the following conditions:

  • Androgenetic Alopecia: This is the medical term for male and female pattern baldness, which is the most common form of hair loss[2].
  • Female Pattern Hair Loss: A specific type of hair loss that affects women[3].
  • Endocrine Therapy-Induced Alopecia: Hair loss caused by hormone therapy treatments, often used in breast cancer patients[1].

How Minoxidil Works

While the exact mechanism of action is not fully understood, researchers have some insights into how minoxidil promotes hair growth:

  • It’s believed to widen blood vessels and open potassium channels, increasing blood flow to hair follicles[4].
  • This increased blood flow may stimulate hair follicles, encouraging them to enter the growth phase and potentially increasing the size of hair follicles[2].
  • Minoxidil may also extend the growth phase of hair, leading to longer, thicker hair strands[5].

Forms and Application Methods

Minoxidil is available in several forms:

  • Topical solution: A liquid that is applied directly to the scalp, typically in 2% or 5% concentrations[5].
  • Topical foam: A foam formulation that is easier to apply and may cause less irritation for some users[2].
  • Oral tablets: A newer form being studied for both hair loss and other conditions[1].

The application method depends on the form used. Topical solutions and foams are typically applied once or twice daily to the affected areas of the scalp. Oral minoxidil is taken as prescribed by a doctor[1].

Effectiveness of Minoxidil

Research has shown that minoxidil can be effective in treating hair loss:

  • Studies have demonstrated increased hair count and hair density in many users after several months of use[5].
  • The 5% solution has been found to be more effective than the 2% solution in some studies[5].
  • Results can vary between individuals, and it may take several months to see noticeable improvements[2].

Potential Side Effects

While minoxidil is generally considered safe, it can cause some side effects:

  • Scalp irritation, itching, or redness at the application site[6].
  • Unwanted hair growth in other areas (if the medication spreads to other parts of the body)[3].
  • Rarely, more serious side effects like rapid heartbeat or weight gain may occur, especially with oral minoxidil[1].

Ongoing Research and Future Prospects

Researchers continue to study minoxidil to improve its effectiveness and explore new applications:

  • Combination therapies with other hair loss treatments like finasteride are being investigated[7].
  • Low-dose oral minoxidil is being studied as an alternative to topical applications[1].
  • New formulations, such as minoxidil in a “milky lotion” form, are being developed to potentially reduce side effects and improve user experience[6].
Aspect Details
Formulations Studied Topical solutions (2% and 5%), foams (5%), milky lotions, oral tablets
Conditions Targeted Androgenetic alopecia, female pattern hair loss, endocrine therapy-induced alopecia
Key Outcome Measures Hair density, hair count, hair thickness, scalp coverage, patient satisfaction
Safety Assessments Monitoring for local and systemic side effects, adverse events
Novel Approaches Combination therapies (e.g., minoxidil + finasteride), comparison of different formulations
Duration of Trials Ranging from 12 weeks to 52 weeks
Patient Populations Males and females with various types of hair loss, including breast cancer patients

FAQ

  • What is minoxidil and how does it work for hair loss? Minoxidil is a medication that was originally developed to treat high blood pressure but was found to promote hair growth. It works by widening blood vessels and increasing blood flow to hair follicles, which may stimulate hair growth and slow hair loss. It's available in topical and oral forms for treating various types of hair loss.
  • What types of hair loss are being studied with minoxidil in clinical trials? Clinical trials are investigating minoxidil for several types of hair loss, including androgenetic alopecia (male and female pattern baldness), female pattern hair loss, and endocrine therapy-induced alopecia in breast cancer patients.
  • What formulations of minoxidil are being tested? Various formulations are being studied, including topical solutions (2% and 5%), foams (5%), milky lotions, and oral tablets. Some trials are comparing different formulations to determine which is most effective and well-tolerated.
  • Are there any new combinations being tested with minoxidil? Yes, some trials are exploring combinations of minoxidil with other hair loss treatments. For example, one study is investigating a combination of topical minoxidil 5% and finasteride 0.1% compared to minoxidil 5% alone for male androgenetic alopecia.
  • What are the main outcomes being measured in these clinical trials? The main outcomes being measured include changes in hair density, hair count, hair thickness, scalp coverage, and patient satisfaction. Safety assessments, including monitoring for side effects and adverse events, are also important components of these trials.

Ongoing Clinical Trials on Minoxidil

  • Study on the Effectiveness and Safety of Oral Minoxidil for Women with Androgenetic Alopecia

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Portugal Spain

Glossary

  • Androgenetic Alopecia: A common form of hair loss in both men and women, also known as male or female pattern baldness. It is characterized by a progressive thinning of hair on the scalp, typically in specific patterns.
  • Endocrine Therapy-Induced Alopecia (EIA): Hair loss that occurs as a side effect of endocrine therapy, which is commonly used in the treatment of breast cancer. This type of hair loss can be distressing for patients and may lead to reduced quality of life.
  • Topical Application: A method of applying medication directly to the skin or scalp. In the case of minoxidil, this often involves applying a solution, foam, or lotion to the affected areas of the scalp.
  • Efficacy: The ability of a treatment to produce the desired result. In minoxidil trials, efficacy is often measured by improvements in hair growth, density, or thickness.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This is important for understanding how different formulations of minoxidil may affect its effectiveness and safety.
  • Target Area Hair Count (TAHC): A method used in clinical trials to measure the number of hairs in a specific area of the scalp, often used to assess the effectiveness of hair loss treatments.
  • Vellus Hair: Fine, short, light-colored hair that is often barely noticeable. In hair loss studies, the ratio of vellus to terminal (thicker, longer) hairs is sometimes measured to assess treatment effectiveness.

References

  1. https://clinicaltrials.gov/study/NCT05417308
  2. https://clinicaltrials.gov/study/NCT00151515
  3. https://clinicaltrials.gov/study/NCT00958750
  4. https://clinicaltrials.gov/study/NCT05272462
  5. https://clinicaltrials.gov/study/NCT01145625
  6. https://clinicaltrials.gov/study/NCT01650272
  7. https://clinicaltrials.gov/study/NCT05990400